Comparing Lumenis (LMNS) & Spectranetics Corp (NASDAQ:SPNC)

Spectranetics Corp (NASDAQ: SPNC) and Lumenis (NASDAQ:LMNS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for Spectranetics Corp and Lumenis, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spectranetics Corp 0 8 1 0 2.11
Lumenis 0 0 0 0 N/A

Spectranetics Corp currently has a consensus target price of $34.14, suggesting a potential downside of 11.20%. Given Spectranetics Corp’s higher possible upside, equities analysts clearly believe Spectranetics Corp is more favorable than Lumenis.


This table compares Spectranetics Corp and Lumenis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spectranetics Corp -32.93% -194.18% -23.25%
Lumenis 2.40% 6.50% 2.39%

Earnings and Valuation

This table compares Spectranetics Corp and Lumenis’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Spectranetics Corp $284.59 million 5.91 -$17.81 million ($1.59) -24.18
Lumenis N/A N/A N/A N/A N/A

Lumenis has higher revenue, but lower earnings than Spectranetics Corp.

Institutional and Insider Ownership

92.0% of Spectranetics Corp shares are held by institutional investors. 3.7% of Spectranetics Corp shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Spectranetics Corp beats Lumenis on 5 of the 8 factors compared between the two stocks.

About Spectranetics Corp

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads. Its geographic segments are U.S. Medical and International Medical. Its product offerings in U.S. Medical segment include medical devices used in minimally invasive procedures within the cardiovascular system, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment) and the service of the excimer laser system (service). Its products are used in multiple vascular procedures, including peripheral atherectomy, crossing arterial blockages, coronary atherectomy and thrombectomy. Its International Medical segment is primarily engaged in distribution activities.

About Lumenis

Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies. It offers products to hospitals, outpatient clinics, ambulatory surgery centers, physicians’ offices, private clinics and aesthetic chains. Its locations include Yokneam, Israel, where surgical and aesthetic products are manufactured, and Salt Lake City, Utah, where ophthalmic products are manufactured.

Receive News & Ratings for Spectranetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectranetics Corp and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply